Novartis ranks first in 2024 Access to Medicine Index The Index spotlights Novartis leadership in research and development, and governance of access, with Novartis ranking first in these sub-topics Novartis malaria access plans, widespread registration...

New research reveals the critical actions needed to ensure COVID-19-driven surge in virtual health and care drives health access and equity COVID-19 pandemic triggered a massive surge in virtual health and care delivery across the world, with many countries embracing hybrid virtual and in-person services Report from the Broadband...

Novartis pledges 10-year commitment with Morehouse School of Medicine, 26 Historically Black Colleges, Universities, Medical Schools and other leading organizations to co-create effective, measurable solutions for health equity Novartis and the Novartis US Foundation to join forces with Thurgood Marshall College Fund, Morehouse School of Medicine, 26 other Historically Black Colleges, Universities and Medical Schools and...

Novartis announces collaboration with Molecular Partners to develop two DARPin® therapies designed for potential use against COVID-19 Novartis has been granted an option to in-license global rights of MP0420 and MP0423 - multi-targeted direct acting antiviral therapeutic candidates demonstrating potential efficacy against...

Novartis announces plan to initiate clinical study of Jakavi® in severe COVID-19 patients and establish international compassionate use program New clinical trial to evaluate Jakavi® (ruxolitinib) in patients with COVID-19 associated cytokine storm  Cytokine storm is a type of severe immune overreaction that can result from coronavirus...